Buys | $0 | 0 | 0 |
Sells | $23,079 | 4 | 100 |
Buller Richard E | director | 0 | $0 | 4 | $23,079 | $-23,079 |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Over the last 12 months, insiders at Celcuity Inc. have bought $0 and sold $23,079 worth of Celcuity Inc. stock.
On average, over the past 5 years, insiders at Celcuity Inc. have bought $850,494 and sold $114,142 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $103,187 was made by Furcht Leo (director) on 2023‑05‑22.
2024-10-23 | Sale | Buller Richard E | director | 350 0.0009% | $16.25 | $5,688 | -20.26% | |
2024-08-23 | Sale | Buller Richard E | director | 350 0.0009% | $16.95 | $5,933 | -24.58% | |
2024-06-21 | Sale | Buller Richard E | director | 350 0.0011% | $15.68 | $5,488 | -7.97% | |
2024-04-24 | Sale | Buller Richard E | director | 350 0.0011% | $17.06 | $5,971 | -11.33% | |
2024-02-21 | Sale | Buller Richard E | director | 350 0.0014% | $14.15 | $4,953 | +9.41% | |
2023-12-20 | Sale | Buller Richard E | director | 350 0.0015% | $14.37 | $5,030 | +9.12% | |
2023-12-15 | Sale | Dalvey David | director | 2,940 0.0121% | $14.57 | $42,847 | +6.71% | |
2023-12-14 | Sale | Dalvey David | director | 5,000 0.0206% | $14.75 | $73,752 | +6.35% | |
2023-12-13 | Sale | Dalvey David | director | 5,000 0.0202% | $14.50 | $72,500 | +6.32% | |
2023-12-12 | Sale | Dalvey David | director | 2,060 0.0085% | $14.61 | $30,089 | +9.27% | |
2023-12-08 | Sale | Dalvey David | director | 5,000 0.0207% | $15.00 | $75,000 | +6.50% | |
2023-12-07 | Sale | Dalvey David | director | 5,000 0.0207% | $14.85 | $74,250 | +6.14% | |
2023-10-25 | Sale | Buller Richard E | director | 350 0.0016% | $10.23 | $3,581 | +55.32% | |
2023-08-30 | Sale | Buller Richard E | director | 350 0.0015% | $9.28 | $3,248 | +58.21% | |
2023-08-23 | Sale | Buller Richard E | director | 300 0.0013% | $9.82 | $2,946 | +46.64% | |
2023-06-23 | Sale | Buller Richard E | director | 300 0.0014% | $11.79 | $3,537 | +25.70% | |
2023-05-23 | Sale | Buller Richard E | director | 75 0.0003% | $11.10 | $833 | +19.55% | |
2023-05-22 | Sale | Buller Richard E | director | 100 0.0005% | $10.50 | $1,050 | +22.55% | |
2023-05-22 | Furcht Leo | director | 10,000 0.0449% | $10.32 | $103,187 | +22.55% | ||
2023-05-19 | Sale | Buller Richard E | director | 250 0.0011% | $9.85 | $2,463 | +23.81% |
Buller Richard E | director | 6681 0.018% | $67,010.43 | 0 | 26 | |
Sullivan Brian F. | Chief Executive Officer | 3016643 8.1246% | $30.26M | 1 | 0 | +9.33% |
Dalvey David | director | 225000 0.606% | $2.26M | 0 | 6 | |
NIGON RICHARD | director | 96032 0.2586% | $963,200.96 | 7 | 0 | +17.87% |
Furcht Leo | director | 10250 0.0276% | $102,807.50 | 1 | 0 | +22.55% |
Murphy Polly A. | director | 5000 0.0135% | $50,150.00 | 1 | 0 | +10.68% |
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $340.18M | |
$73,222,926 | 18 | 60.19% | $406.4M | |
$14,865,077 | 18 | -28.56% | $389.16M | |
$276,750,010 | 16 | -7.95% | $385.21M | |
$46,442,839 | 15 | -20.05% | $391.15M | |
$7,254,955 | 14 | 20.70% | $359.58M | |
$18,945,106 | 14 | -27.94% | $352.6M | |
$65,355,913 | 13 | -3.42% | $367.14M | |
$1,037,470 | 13 | 78.00% | $381.85M | |
$81,667,942 | 12 | -57.54% | $360.65M | |
Celcuity Inc. (CELC) | $3,073,199 | 10 | 16.77% | $372.41M |
$52,263,118 | 10 | -6.89% | $406.76M | |
$4,706,376 | 8 | 42.30% | $347.52M | |
$3,677,917 | 5 | 10.19% | $400.55M | |
$51,588,185 | 5 | 19.18% | $364M | |
$79,238,118 | 4 | -26.47% | $394.44M | |
$8 | 2 | 28.83% | $351.07M | |
$960,000 | 2 | 15.91% | $404.49M |
Increased Positions | 55 | +46.61% | 4M | +14.43% |
Decreased Positions | 50 | -42.37% | 4M | -14.44% |
New Positions | 20 | New | 1M | New |
Sold Out Positions | 21 | Sold Out | 927,186 | Sold Out |
Total Postitions | 123 | +4.24% | 30M | -0.02% |
Bvf Inc/Il | $32,684.00 | 9.37% | 3.47M | 0 | 0% | 2024-12-31 |
Baker Bros. Advisors Lp | $25,259.00 | 7.24% | 2.68M | +803,575 | +42.86% | 2024-12-31 |
Soleus Capital Management, L.P. | $24,189.00 | 6.93% | 2.57M | +1M | +105.97% | 2024-12-31 |
Perceptive Advisors Llc | $22,276.00 | 6.39% | 2.36M | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $20,549.00 | 5.89% | 2.18M | +368,616 | +20.36% | 2024-12-31 |
Vanguard Group Inc | $15,578.00 | 4.47% | 1.65M | +24,429 | +1.5% | 2024-12-31 |
Eventide Asset Management, Llc | $11,935.00 | 3.42% | 1.27M | -269,347 | -17.55% | 2024-12-31 |
Samlyn Capital, Llc | $11,803.00 | 3.38% | 1.25M | -39,342 | -3.05% | 2024-12-31 |
Nea Management Company, Llc | $11,788.00 | 3.38% | 1.25M | 0 | 0% | 2024-12-31 |
Saturn V Capital Management Lp | $10,031.00 | 2.88% | 1.06M | +117,448 | +12.41% | 2024-12-31 |